New England Claims $2 Billion Slice of 2016 Pharmaceutical-Biotech Capital/MRO Investment Pie
New England Claims $2 Billion Slice of 2016 Pharmaceutical-Biotech Capital/MRO Investment Pie
Attachment: New England pharma
SUGAR LAND--January 18, 2016--Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas)--New England, a major darling of the life science industry, enters the New Year with just over $2 billion in capital and MRO (maintenance) projects scheduled for kick-off within the next 12 months. This is a projected boost of 25% over the region's 2015 kick-off count. Within this article: Details of top life science project kickoffs in New England for 2016, including those by Siemen AG (NYSE:SI) and Alnylam Pharmaceutical (NASDAQ:ALNY).
Subscribe Now!(All Fields Required)
Related Articles
Articles related to this company
- Siemens' 10 Top-Valued U.S. Projects Point to Growth of Shale Gas Demand
- New England Scores Another Touchdown as 1Q17 Pharma-Bio Project Starts Top ...
- Pharma-Biotech North American Construction Investment Review: 2016 Project ...
- New England Sees More than $10 Billion on the Horizon for Project Kickoffs ...
- New England Boasts More than $2 Billion in Second-Quarter 2016 Project Kick...